Rated 3.2 / 5 (How Ratings Work)
Likely probability of the efficacy of cannabis for treatment of multiple sclerosis (ms).
Based on 47 Studies from 1981 - 2018
Study Name, Description & Year
Rating
Hypoxia Mimetic Activity Of VCE-004.8, A Cannabidiol Quinone Derivative: Implications For Multiple Sclerosis Therapy
Laboratory Study — 2018
2-AG Limits Theiler's Virus Induced Acute Neuroinflammation By Modulating Microglia And Promoting MDSCs
Laboratory Study — 2018
Systematic Review Of Systematic Reviews For Medical Cannabinoids: Pain, Nausea And Vomiting, Spasticity, And Harms
Medical cannabinoids — 2018
The Use Of Cannabis And Cannabinoids In Treating Symptoms Of Multiple Sclerosis: A Systematic Review Of Reviews
A review of reviews, of 11 eligible reviews providing data from 32 studies, including 10 moderate to high quality RCTs. — 2018
Cannabinoids For Treating Neurogenic Lower Urinary Tract Dysfunction In Patients With Multiple Sclerosis: A Systematic Review And Meta-analysis
Meta-analysis — 2017
Neurological Aspects Of Medical Use Of Cannabidiol
Review/Meta-Analysis — 2017
(−)-β-Caryophyllene, A CB2 Receptor-Selective Phytocannabinoid, Suppresses Motor Paralysis And Neuroinflammation In A Murine Model Of Multiple Sclerosis
Animal study (mice) — 2017
A Cost-effectiveness Model For The Use Of A Cannabis-derived Oromucosal Spray For The Treatment Of Spasticity In Multiple Sclerosis
Statistical method (Markov model) — 2016
THC:CBD Observational Study Data: Evolution Of Resistant MS Spasticity And Associated Symptoms
Ongoing survey conducted on patients with treatment-resistant multiple sclerosis (MS) — 2016
THC:CBD In Daily Practice: Available Data From UK, Germany And Spain
Survey conducted on more than 900 patients with treatment-resistant multiple sclerosis (MS) spasticity. — 2016
The Effect Of Cannabinoids On The Stretch Reflex In Multiple Sclerosis Spasticity
Human trial conducted on 57 MS patients with spasticity — 2016
Efficacy And Safety Of Cannabinoid Oromucosal Spray For Multiple Sclerosis Spasticity
A Survey of data collected from 1615 patients were recruited from 30 MS centres across Italy. — 2016
ENDOCANNABINOID SYSTEM: A Multi-facet Therapeutic Target
Review — 2016
Tetrahydrocannabinol:Cannabidiol Oromucosal Spray For Multiple Sclerosis-Related Resistant Spasticity In Daily Practice
A human trial conducted on 433 patients with MS. — 2016
Endocannabionoid System In Neurological Disorders
Review — 2016
Efficacy And Safety Of Nabiximols (Sativex(®)) On Multiple Sclerosis Spasticity In A Real-life Italian Monocentric Study
A survey conducted on 144 patients with MS. — 2016
Cannabinoid Receptors And Endocannabinoids: Role In Neuroinflammatory And Neurodegenerative Disorders
Literature review — 2010
A Cannabinoid Agonist Interferes With The Progression Of A Chronic Model Of Multiple Sclerosis By Downregulating Adhesion Molecules
Animal study (mice) — 2009
Psychopathological And Cognitive Effects Of Therapeutic Cannabinoids In Multiple Sclerosis: A Double-blind, Placebo Controlled, Crossover Study
17 patients with MS: double-blind, placebo-controlled, crossover study — 2009
Cannabinoid-induced Effects On The Nociceptive System: A Neurophysiological Study In Patients With Secondary Progressive Multiple Sclerosis
18 patients with MS: randomized, double-blind, placebo-controlled, crossover study — 2009
Abnormalities In The Cerebrospinal Fluid Levels Of Endocannabinoids In Multiple Sclerosis
50 patients with MS and 20 control subjects — 2008
Current Status Of Cannabis Treatment Of Multiple Sclerosis With An Illustrative Case Presentation Of A Patient With MS, Complex Vocal Tics, Paroxysmal Dystonia, And Marijuana Dependence Treated With Dronabinol
Case study of a 52-year-old woman with MS, paroxysmal dystonia, complex vocal tics, and cannabis dependence. — 2008
Oromucosal Delta9-tetrahydrocannabinol/cannabidiol For Neuropathic Pain Associated With Multiple Sclerosis: An Uncontrolled, Open-label, 2-year Extension Trial
66 patients with MS — 2007
Randomized Controlled Trial Of Cannabis-based Medicine In Spasticity Caused By Multiple Sclerosis
189 patients with MS — 2007
The Endocannabinoid System Is Dysregulated In Multiple Sclerosis And In Experimental Autoimmune Encephalomyelitis
26 patients with MS, 25 healthy controls, and an animal study (mice) — 2007
Control Of Spasticity In A Multiple Sclerosis Model Is Mediated By CB1, Not CB2, Cannabinoid Receptors
Animal study (mice) — 2007
The Cannabinergic System As A Target For Anti-inflammatory Therapies
Laboratory — 2006
The Effect Of Cannabis On Urge Incontinence In Patients With Multiple Sclerosis: A Multicentre, Randomised Placebo-controlled Trial (CAMS-LUTS)
630 MS patients — 2006
Sativex: Clinical Efficacy And Tolerability In The Treatment Of Symptoms Of Multiple Sclerosis And Neuropathic Pain
Patients with MS — 2006
Therapeutic Action Of Cannabinoid On Axonal Injury Induced By Peroxynitrite
Animal study (rats) — 2006
Cannabinoide Bei Multipler Sklerose - Therapeutisch Sinnvoll? [Cannabinoids In Multiple Sclerosis -- Therapeutically Reasonable?]
A meta-analysis of human, animal, and laboratory studies — 2005
Randomized, Controlled Trial Of Cannabis-based Medicine In Central Pain In Multiple Sclerosis
66 patients with MS — 2005
Sativex For The Management Of Multiple Sclerosis Symptoms
Meta-analysis on 368 human patients with various neurological disorders including MS — 2005
Randomized, Controlled Trial Of Cannabis-based Medicine In Central Pain In Multiple Sclerosis
66 patients with MS — 2005
Do Cannabis-based Medicinal Extracts Have General Or Specific Effects On Symptoms In Multiple Sclerosis? A Double-blind, Randomized, Placebo-controlled Study On 160 Patients
160 outpatients with MS — 2004
An Open-label Pilot Study Of Cannabis-based Extracts For Bladder Dysfunction In Advanced Multiple Sclerosis
15 MS patients with lower urinary tract symptoms — 2004
Cannabis Use As Described By People With Multiple Sclerosis
420 patients with MS — 2003
Cannabinoids Control Spasticity And Tremor In A Multiple Sclerosis Model
Animal study (mice) — 2000
The Perceived Effects Of Smoked Cannabis On Patients With Multiple Sclerosis
112 patients with MS — 1997
Nabilone In The Treatment Of Multiple Sclerosis
1 patient with MS — 1995
Short-term Effects Of Smoking Marijuana On Balance In Patients With Multiple Sclerosis And Normal Volunteers
10 MS patients and 10 normal volunteers — 1994
Effect Of Cannabinoids On Spasticity And Ataxia In Multiple Sclerosis
1 MS patient — 1989
Delta-9-THC In The Treatment Of Spasticity Associated With Multiple Sclerosis
13 MS patients — 1987
Treatment Of Human Spasticity With Delta 9-tetrahydrocannabinol
9 patients suffering from spasticity from various etiologies including MS — 1981